Thera-SAbDab

SARILUMAB

>   Structural Summary
TherapeuticSarilumab
TargetIL6R
Heavy ChainEVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS
Light ChainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyVelocImmune Mouse
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAsahi Kasei Pharma Corp, Regeneron Pharmaceuticals, Sanofi
Conditions ApprovedRheumatoid arthritis
Conditions ActiveGiant cell arteritis, Polymyalgia rheumatica, Juvenile rheumatoid arthritis, Uveitis
Conditions DiscontinuedAnkylosing spondylitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]